This product needs to be purchased after filling out a questionnaire and conducting a simple online consultation to obtain a prescription.
The questionnaire and online consultation take approximately 5 minutes each.
Mounjaro (Tirzepatide) is an innovative drug developed by Eli Lilly and Company.
As a dual receptor agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), it has the dual effects of improving weight management and blood sugar control.
Mounjaro is injected once a week and is suitable for obese or overweight adults, especially those with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidemia, etc.).
